All the above evidence illustrated that low m6A score group with low progression probability might be associated with higher immune cell infiltration and better response to immunotherapy, and high m6A score group with high possibility of metastasis might possess more activated NF-κB pathway and higher cancer stemness index. The gene discussed is NFKB1; the disease is cancer.